Enanta Pharmaceuticals (ENTA) Non-Current Deffered Revenue (2012 - 2019)
Enanta Pharmaceuticals posted quarterly Non-Current Deffered Revenue of $900000.0 for Q3 2019, up 51.77% year-on-year from $593000.0 in Q3 2018, and down 2.49% on a QoQ basis from $923000.0 in Q2 2019.
Enanta Pharmaceuticals (ENTA) has 8 years of Non-Current Deffered Revenue data on file, last reported at $900000.0 in Q3 2019.
- For the quarter ending Q3 2019, Non-Current Deffered Revenue rose 51.77% year-over-year to $900000.0; the trailing twelve-month figure through Sep 2019 stood at $900000.0 (up 51.77% YoY), and the FY2019 full-year result was $900000.0, up 51.77% from the prior year.
- Non-Current Deffered Revenue for Q3 2019 stood at $900000.0, down from $923000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $923000.0 in Q2 2019 and bottomed at $161000.0 in Q1 2015.
- The 5-year median for Non-Current Deffered Revenue is $674000.0 (2018), against an average of $650789.5.
- The widest annual swing landed in 2015, when Non-Current Deffered Revenue jumped 322.22%; it then retreated 14.06% in 2018.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $646000.0 in 2015, then gained by 8.51% to $701000.0 in 2016, then decreased by 6.7% to $654000.0 in 2017, then grew by 3.06% to $674000.0 in 2018, then jumped by 33.53% to $900000.0 in 2019.
- The last three Non-Current Deffered Revenue figures came in at $900000.0 (Q3 2019), $923000.0 (Q2 2019), and $842000.0 (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 900,000.00 |
| Jun 30, 2019 | 923,000.00 |
| Mar 31, 2019 | 842,000.00 |
| Dec 31, 2018 | 674,000.00 |
| Sep 30, 2018 | 593,000.00 |
| Jun 30, 2018 | 611,000.00 |
| Mar 31, 2018 | 632,000.00 |
| Dec 31, 2017 | 654,000.00 |
| Sep 30, 2017 | 676,000.00 |
| Jun 30, 2017 | 711,000.00 |
| Mar 31, 2017 | 706,000.00 |
| Dec 31, 2016 | 701,000.00 |
| Sep 30, 2016 | 696,000.00 |
| Jun 30, 2016 | 682,000.00 |
| Mar 31, 2016 | 664,000.00 |
| Dec 31, 2015 | 646,000.00 |
| Sep 30, 2015 | 628,000.00 |
| Jun 30, 2015 | 265,000.00 |
| Mar 31, 2015 | 161,000.00 |
| Dec 31, 2014 | 153,000.00 |
| Sep 30, 2014 | 153,000.00 |
| Dec 31, 2013 | 133,000.00 |
| Sep 30, 2013 | 127,000.00 |
| Jun 30, 2013 | 114,000.00 |
| Mar 31, 2013 | 101,000.00 |
| Sep 30, 2012 | 75,000.00 |